國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁 到查詢結果 [ subject:"Cancer Research." ]

切換: 標籤 | MARC模式 | ISBD

Immunotherapy

Hajjar, Joud.

Immunotherapy

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Immunotherapyedited by Aung Naing, Joud Hajjar.
其他作者:	Hajjar, Joud.
出版者:	Cham :Springer International Publishing :2018.
面頁冊數:	viii, 182 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	CancerImmunological aspects.
電子資源:	https://doi.org/10.1007/978-3-030-02505-2
ISBN:	9783030025052$q(electronic bk.)

Immunotherapy
Immunotherapy[electronic resource] /edited by Aung Naing, Joud Hajjar. - 2nd ed. - Cham :Springer International Publishing :2018. - viii, 182 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.9950065-2598 ;. - Advances in experimental medicine and biology ;946..

Overview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies.

The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.

ISBN: 9783030025052$q(electronic bk.)

Standard No.: 10.1007/978-3-030-02505-2doiSubjects--Topical Terms:

484440
Cancer
--Immunological aspects.

LC Class. No.: RC268.3 / .I468 2018

Dewey Class. No.: 616.994079

Immunotherapy
LDR:03393nmm a2200349 a 4500 001 546674
003 DE-He213
005 20190509090616.0
006 m d
007 cr nn 008maaau
008 190627s2018 gw s 0 eng d
020 $a 9783030025052$q(electronic bk.)
020 $a 9783030025045$q(paper)
024 7 $a 10.1007/978-3-030-02505-2 $2 doi
035 $a 978-3-030-02505-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC268.3 $b .I468 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994079 $2 23
090 $a RC268.3 $b .I33 2018
245 0 0 $a Immunotherapy $h [electronic resource] / $c edited by Aung Naing, Joud Hajjar.
250 $a 2nd ed.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a viii, 182 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.995
505 0 $a Overview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies.
520 $a The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
650 0 $a Cancer $x Immunological aspects. $3 484440
650 0 $a Oncology. $3 195181
650 1 4 $a Cancer Research. $3 273660
700 1 $a Hajjar, Joud. $3 775191
700 1 $a Naing, Aung. $3 775190
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u https://doi.org/10.1007/978-3-030-02505-2
950 $a Biomedical and Life Sciences (Springer-11642)